LRG Research Team

Home/Tag: LRG Research Team

LRG researchers publish study on DREAM complex – an important regulator of GIST “cell sleep”

A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.

By |2019-09-20T12:24:44-04:00July 5th, 2013|News, Research|

How ‘Next Generation’ DNA sequencing is changing the landscape of GIST research and diagnosis

During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.

By |2019-09-20T12:32:28-04:00June 11th, 2013|News, Research|

Breaking Research Barriers – Our Unique Team Searches for a Cure

Breaking Research Barriers! The Life Raft Group Research Team is unique. As we know, the purpose of research is to inform, educate and allow us to live better lives.

By |2018-08-01T14:32:17-04:00June 4th, 2013|Fundraising, News, Research, Video|

It Will Take Not One Hero but Many: Collaborating for a Cure

Time magazine this month published an in-depth look at how collaboration is beginning to change the way cancer research is approached, citing numerous examples of the effectiveness of scientists working together to find a cure.

By |2019-09-20T12:45:27-04:00April 19th, 2013|News, Research|

Stivarga becomes first FDA-approved third-line drug treatment for GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.

By |2019-09-20T12:49:52-04:00April 1st, 2013|Drug Treatment, News, Side Effects, Stivarga|
Go to Top